Seizure control after chronic pharmacotherapy in epileptic disorders beginning after 40 years of age.

abstract：:Aminopyridines are members of a family of monoamino and diamino derivatives of pyridine, and their principal mechanism of action is dose-dependent blockade of voltage-gated potassium channels, in particular, fast voltage-gated potassium channels. To date, only 2 main broad-spectrum potassium channel blockers, 4-aminop...

journal_title：Clinical neuropharmacology

authors： Sedehizadeh S,Keogh M,Maddison P

更新日期：2012-07-01 00:00:00

abstract：INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...

journal_title：Clinical neuropharmacology

authors： Dang D,Cunnington D,Swieca J

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Catatonia is a severe condition in patients. Electroconvulsive treatment or medication with benzodiazepines and/or antipsychotics are regarded as standard treatment. CASE PRESENTATION:We report a case of a patient with catatonic features in whom electroconvulsive treatment and benzodiazepine and/or antipsyc...

journal_title：Clinical neuropharmacology

authors： Sato Y,Shinozaki M,Okayasu H,Yasui-Furukori N,Shimoda K

更新日期：2020-05-01 00:00:00

abstract：:Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

journal_title：Clinical neuropharmacology

authors： Giménez-Roldán S,Esteban EM,Mateo D

更新日期：2001-11-01 00:00:00

abstract：:Tremors other than those associated with Parkinson's disease are commonly encountered in clinical practice. The differentiation of tremor subtypes depends primarily on the presence of distinct clinical characteristics and is facilitated by the use of consistent nomenclature. Such differentiation can be helpful in dete...

journal_title：Clinical neuropharmacology

authors： O'Sullivan JD,Lees AJ

更新日期：2000-09-01 00:00:00

abstract：OBJECTIVES:Persistent sequelae of lithium intoxication gained clinical attention in the 1980s and were named Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). The authors review the published cases of SILENT reported in the literature and discuss various clinical manifestations. METHODS:The authors'...

journal_title：Clinical neuropharmacology

authors： Adityanjee,Munshi KR,Thampy A

更新日期：2005-01-01 00:00:00

abstract：:The description of multiple classes of opioid receptors has had a major impact on our understanding of the mechanisms of analgesia. Three major classes of opioid receptors have been defined: mu, kappa, and delta. The mu receptors have been further subclassified into two distinct subtypes (mu 1 and mu 2), as have the d...

journal_title：Clinical neuropharmacology

authors： Pasternak GW

更新日期：1993-02-01 00:00:00

abstract：BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

journal_title：Clinical neuropharmacology

authors： Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

更新日期：2011-01-01 00:00:00

abstract：:Depression frequently coexists with dementia, although in many cases the depression is not recognized clinically. Depression represents a major additional burden in dementia, not only for the patients but also for families, caregivers, and, economically, society as a whole. However, depression in patients with dementi...

journal_title：Clinical neuropharmacology

authors： De Vry J,Fritze J,Post RM

更新日期：1997-02-01 00:00:00

abstract：:Glutamine synthetase (GS), an enzyme localized in astroglial cells in the brain, is directly implicated in brain detoxification. An ontogenic study of GS activity was performed in homogenates from four distinct brain areas in comparison with the respective astrocytes obtained in primary cultures. GS was induced by hyd...

journal_title：Clinical neuropharmacology

authors： Tardy M,Rolland B,Fages C,Caldani M

更新日期：1984-01-01 00:00:00

abstract：:In rodents, serotonin (5-HT) antagonists counteract behavioral and biochemical effects of neuroleptic drugs. Therefore, we have studied the effect of different 5-HT drugs and one anticholinergic drug in acute dystonia in five cebus monkeys chronically treated with haloperidol. Acute dystonia induced by subcutaneous in...

journal_title：Clinical neuropharmacology

authors： Povlsen UJ,Noring U,Laursen AL,Korsgaard S,Gerlach J

更新日期：1986-01-01 00:00:00

abstract：OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

journal_title：Clinical neuropharmacology

authors： Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

更新日期：2014-09-01 00:00:00

abstract：:The pyrimidine nucleosides uridine (URI) and cytidine (CYT), alone or associated with n-acetyl-glutamine (NAG), were injected acutely or subchronically to aged (26 months old) male rats of the Sprague-Dawley strain. Learning and memory abilities of the animals were studied with tests of avoidance behavior. The acquisi...

journal_title：Clinical neuropharmacology

authors： Drago F,D'Agata V,Valerio C,Spadaro F,Raffaele R,Nardo L,Grassi M,Freni V

更新日期：1990-08-01 00:00:00

abstract：:The extensive use of the Unified Parkinson's Disease Rating Scale (UPDRS) has revealed low interrater reliability in some items and redundancy in others. In view of these shortcomings, we have structured a new scale that includes a zero-to three-point scale for each item in the evaluation of PD. The mental axis includ...

journal_title：Clinical neuropharmacology

authors： Rabey JM,Bass H,Bonuccelli U,Brooks D,Klotz P,Korczyn AD,Kraus P,Martinez-Martin P,Morrish P,Van Sauten W,Van Hilten B

更新日期：1997-08-01 00:00:00

abstract：:The effects of the psychotropic drug etoperidone on the response to laboratory stressors was investigated in a controlled study. Cardiovascular and hormonal (catecholamines, corticotropin, and cortisol) measurements were made in a group of young, healthy volunteers during a cold pressor test (CPT), a mental arithmetic...

journal_title：Clinical neuropharmacology

authors： Costa A,Martignoni E,Blandini F,Petraglia F,Genazzani AR,Nappi G

更新日期：1993-04-01 00:00:00

abstract：OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

journal_title：Clinical neuropharmacology

authors： Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

更新日期：2010-01-01 00:00:00

abstract：:Age-associated memory impairment (AAMI) is a diagnostic term applied to healthy persons greater than 50 years of age who have experienced a gradual decline in memory that lies within the boundaries of normality. Although the behavioral deficits associated with AAMI are modest in comparison to those associated with dem...

journal_title：Clinical neuropharmacology

authors： Crook TH,Larrabee GJ,Youngjohn JR

更新日期：1990-01-01 00:00:00

abstract：:We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...

journal_title：Clinical neuropharmacology

authors： Keränen T,Gordin A,Harjola VP,Karlsson M,Korpela K,Pentikäinen PJ,Rita H,Seppälä L,Wikberg T

更新日期：1993-04-01 00:00:00

abstract：OBJECTIVE:Multiple sclerosis (MS) is a degenerative neurological condition that results in impairments in multiple domains including cognition, fatigue, and mood. Dalfampridine-extended release (D-ER) has been approved to improve walking in persons with MS. It is plausible that D-ER could improve cognition, fatigue, an...

journal_title：Clinical neuropharmacology

authors： Triche EW,Ruiz JA,Olson KM,Lo AC

更新日期：2016-03-01 00:00:00

abstract：:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

journal_title：Clinical neuropharmacology

authors： Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

更新日期：1988-02-01 00:00:00

abstract：:Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...

journal_title：Clinical neuropharmacology

authors： Oulis P,Nakkas G,Masdrakis VG

更新日期：2011-03-01 00:00:00

abstract：:A patient with melanoma and sporadic positive melanuria developed Parkinson's disease. Treatment with levodopa failed to modify tumoral progress. However, during chemotherapy with dacarbazine, the patient experienced a significant impairment to levodopa response. ...

journal_title：Clinical neuropharmacology

authors： Merello M,Esteguy M,Perazzo F,Leiguarda R

更新日期：1992-02-01 00:00:00

abstract：:Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importanc...

journal_title：Clinical neuropharmacology

authors： Greenamyre JT

更新日期：2001-03-01 00:00:00

abstract：:The effects of 5-HT are varied and widely distributed throughout the human body. At this time, 5-HT research is a field ripe for "plucking." Not only is there a great demand for more selective agonists and antagonists, but there is more than enough work needed in receptor binding studies to keep pharmacologists employ...

journal_title：Clinical neuropharmacology

authors： Bonate PL

更新日期：1991-02-01 00:00:00

abstract：ABSTRACT:Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Methylphenidate (MPH) is one of the most widely used drugs in the treatment of ADHD. Enuresis can occur comorbidly with ADHD. However, enuresis is sometimes seen in patients with ADHD as an adve...

journal_title：Clinical neuropharmacology

authors： Uzun N,Akinci MA,Karatoprak S

更新日期：2021-01-01 00:00:00

abstract：:This article outlines the reasons that detection of subtle changes in the cognitive system is difficult in geriatric assessment. A new assessment approach is introduced that examines cognitive patterns and facilitates the evaluation of subtle changes. ...

journal_title：Clinical neuropharmacology

authors： Poon LW

更新日期：1993-01-01 00:00:00

abstract：:The suppressive roles of adrenergic stimulation and rapid eye movement (REM) sleep on human prolactin (PRL) secretion are controversial. We examined the effects of sleep, clonidine (an alpha 2-adrenergic agonist), and their interaction on PRL secretion. Two groups of normal men (nine each) were studied in two morning ...

journal_title：Clinical neuropharmacology

authors： Cavallo A,Carskadon MA,Grocer P

更新日期：1991-10-01 00:00:00

abstract：:Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

journal_title：Clinical neuropharmacology

authors： Malizia AL,Nutt DJ

更新日期：1995-06-01 00:00:00

abstract：:Bupropion hydrochloride (HCl) is an antidepressant that has many different biological targets, acting as both a norepinephrine-dopamine reuptake inhibitor as well as a nicotinic antagonist. This second-generation antidepressant is available in 3 bioequivalent formulations: immediate release, sustained release, and ext...

journal_title：Clinical neuropharmacology

authors： Schwitalla TA,Patel RA,Catalano G,Nirmalani-Gandhy A

更新日期：2019-11-01 00:00:00

abstract：:Modafinil is a psychostimulant compound that is just now becoming available in many countries for treatment of narcoleptic and hypersomnic patients. Whereas sleep attacks and drowsiness can be effectively improved, the drug does not sufficiently reduce cataplectic seizures. It therefore is often used in combination wi...

journal_title：Clinical neuropharmacology

authors： Grözinger M,Härtter S,Hiemke C,Griese EU,Röschke J

更新日期：1998-03-01 00:00:00